Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hycroft Mining Holding Corporation Class A Common Stock (HYMC) vs Natera Inc. Common Stock (NTRA) Price & Performance

Hycroft Mining Holding Corporation Class A Common StockTrade
Natera Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Hycroft Mining Holding Corporation Class A Common Stock vs Natera Inc. Common Stock — how do they compare? Hycroft Mining Holding Corporation Class A Common Stock trades at $16.84 (market cap $1.52B), while Natera Inc. Common Stock trades at $392.78 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 37.5× Hycroft Mining Holding Corporation Class A Common Stock's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Hycroft Mining Holding Corporation Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hycroft Mining Holding Corporation Class A Common Stock for 0 Days and Natera Inc. Common Stock for 0 Days on average.

HYMCNTRA
Market Cap
$1.52B$57.03B
Volume
3,040,9221,131,157
Sector
Basic MaterialsHealth
52-Week High
$55.74$425.64
52-Week Low
$6.75$179.42
Typical Hold Time
0 Days0 Days
Enterprise Value
$1.30B$56.18B

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HYMC
100% Buy0% Sell
Avg holding period · 0 Days
NTRA
100% Buy0% Sell
Avg holding period · 0 Days

About Hycroft Mining Holding Corporation Class A Common Stock

Hycroft Mining Holding Corporation is a US mining company that owns and operates the Hycroft Mine, a gold and silver deposit in northern Nevada, producing and selling gold and silver from open-pit mining operations.

Read more on HYMC →

About Natera Inc. Common Stock

Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.

Read more on NTRA →